Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
fluorouracil + interferon alfa
- Development stage
- Unknown
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes, Small Molecules
- Administration
- Intravenous, Subcutaneous, Intra-arterial, Intramuscular
01
Overview
Fluorouracil + interferon alfa is a combination regimen of two agents used primarily in oncology. Fluorouracil (also known as 5-FU) is a pyrimidine analog antimetabolite that inhibits thymidylate synthase, disrupting DNA synthesis and leading to cell death. Interferon alfa is a cytokine with immunomodulatory and antiproliferative effects; it enhances immune responses against tumor cells and can directly inhibit tumor cell proliferation. The combination has been studied for synergistic antitumor activity in several advanced cancers including hepatocellular carcinoma (HCC), colorectal cancer, esophageal cancer, and gastric cancer. Clinical trials have shown objective response rates in these indications with manageable toxicity profiles[1][2][4][6].
- Other names
- 5-fluorouracil + interferon-alpha5-FU + IFN-alpha5-fluorouracil + recombinant interferon alfa-2a5-fluorouracil + recombinant interferon alpha-2b
02
Targets
IFNAR (Immune system modulation via type I interferon receptor)TS (Thymidylate synthase)
Beyond the preview
Go deeper on fluorouracil + interferon alfa.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on fluorouracil + interferon alfa.